Tirzepatide is a dual GIP and GLP-1 receptor agonist. Where semaglutide works on one receptor, tirzepatide engages two, each tied to a hormone involved in fullness and blood sugar control. For people in the Seattle area, it is the medication behind Bodi Envi's Personalized Compounded Tirzepatide Weight-Management Programs.
The compounded form is prepared by a licensed compounding pharmacy for one named patient, on the strength of that patient's prescription. Dosing follows a plan the licensed provider set: a weekly injection, beginning at the dose the provider chooses and changing only when the provider decides it should.
Compounded medications sit outside FDA approval. Personalized Compounded Tirzepatide is not FDA-approved, is not equivalent to Mounjaro® and Zepbound®, and is not reviewed by the FDA for safety, effectiveness or quality before it is marketed. That is why each prescription rests on a licensed provider's individual judgement. Brand names are trademarks of their respective owners. Compounding pharmacies are regulated by state boards of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards.